Muramyl dipeptide derivative (Soligenix)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMuramyl dipeptide derivative (Soligenix)

Drug Alias Namemuramyl dipeptide derivative (anticancer), DOR BiopharmaMDP derivative (anticancer), DOR Biopharmamuramyl dipeptide derivative (anticancer), EndorexMDP derivative (anticancer), EndorexImmTher

ClassificationBiologics > Protein drugs > Recombinant polypeptide

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsProstatic NeoplasmsColorectal NeoplasmsBreast Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSoligenix Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSoligenix Inc

Active IndicationsN/A

Inactive IndicationsProstatic NeoplasmsColorectal NeoplasmsBreast Neoplasms +[6]

Other Information

ATC CodeN/A